Abstract
Hepatitis C virus (HCV) infection affects millions of people world-wide, and chronic infection can result in end-stage liver disease and hepatocellular carcinoma. Conventional therapy to date has involved combination antiviral therapy including alpha-interferon and ribavirin; response rates with these drugs are variable based on both viral and host factors, such as HCV viral load, HCV genotype, HIV co-infection, host genetic polymorphisms (such as those in the IL28B region), and other factors. Recent advances in HCV treatment have included pegylated forms of alpha-interferon and, more recently, the development of specifically targeted antiviral therapy for HCV (STAT-C) with novel HCV protease inhibitors (PIs) for genotype 1 HCV. Although unlikely to be administered as monotherapy due to the potential for development of HCV PI drug resistance mutations, results of phase II trials of two PIs in development have recently been reported, demonstrating promising therapeutic efficacy of HCV PIs in combination with established conventional treatment. This review outlines the advances and the challenges in the development of these HCV PIs as effective HCV antiviral agents and their role in clinical practice.
Keywords: Chronic Hepatitis C, Antiviral Agents/therapeutic use, Protease inhibitors/therapeutic use, Serine Proteinase Inhibitors, Clinical Trials as topic, Review, Humans, Viral Nonstructural Proteins
Reviews on Recent Clinical Trials
Title: Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials
Volume: 5 Issue: 3
Author(s): Aarthi Chary and Mark Holodniy
Affiliation:
Keywords: Chronic Hepatitis C, Antiviral Agents/therapeutic use, Protease inhibitors/therapeutic use, Serine Proteinase Inhibitors, Clinical Trials as topic, Review, Humans, Viral Nonstructural Proteins
Abstract: Hepatitis C virus (HCV) infection affects millions of people world-wide, and chronic infection can result in end-stage liver disease and hepatocellular carcinoma. Conventional therapy to date has involved combination antiviral therapy including alpha-interferon and ribavirin; response rates with these drugs are variable based on both viral and host factors, such as HCV viral load, HCV genotype, HIV co-infection, host genetic polymorphisms (such as those in the IL28B region), and other factors. Recent advances in HCV treatment have included pegylated forms of alpha-interferon and, more recently, the development of specifically targeted antiviral therapy for HCV (STAT-C) with novel HCV protease inhibitors (PIs) for genotype 1 HCV. Although unlikely to be administered as monotherapy due to the potential for development of HCV PI drug resistance mutations, results of phase II trials of two PIs in development have recently been reported, demonstrating promising therapeutic efficacy of HCV PIs in combination with established conventional treatment. This review outlines the advances and the challenges in the development of these HCV PIs as effective HCV antiviral agents and their role in clinical practice.
Export Options
About this article
Cite this article as:
Chary Aarthi and Holodniy Mark, Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials, Reviews on Recent Clinical Trials 2010; 5 (3) . https://dx.doi.org/10.2174/157488710792007293
DOI https://dx.doi.org/10.2174/157488710792007293 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy
Medicinal Chemistry The Impact of microRNAs in Breast Cancer Angiogenesis and Progression
MicroRNA Relaxin as a Cardiovascular Drug: A Promise Kept
Current Drug Safety Gels and Jellies as a Dosage Form for Dysphagia Patients: A Review
Current Drug Therapy Enzymes as Target Antigens of Liver-Specific Autoimmunity: The Case of Cytochromes P450s
Current Medicinal Chemistry An Experimental and Theoretical Approach to Understand Fever, DENF & its Cure
Infectious Disorders - Drug Targets Oncolytic Viruses: The Best is Yet to Come
Current Cancer Drug Targets A Review on Skin Targeted Delivery of Bioactives as Ultradeformable Vesicles: Overcoming the Penetration Problem
Current Drug Targets Development and Anti-microbial Potential of Topical Formulations Containing Cocos nucifera Linn.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial [Hot Topic: Emerging Viruses: Advances and Challenges (Executive Editor: Thomas W. Geisbert)]
Current Molecular Medicine Editorial
Inflammation & Allergy - Drug Targets (Discontinued) Dendrimers as Biopharmaceuticals: Synthesis and Properties
Current Topics in Medicinal Chemistry Modulating Gut Microbiota: An Emerging Approach in the Prevention and Treatment of Multiple Sclerosis
Current Neuropharmacology Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Nanowired Drug Delivery to Enhance Neuroprotection in Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Hematological Targets of Radiation Damage
Current Drug Targets Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease
Drug Metabolism Letters Quantitative Structure-Activity Relationship Studies on Matrix Metalloproteinase Inhibitors: Hydroxamic Acid Analogs
Medicinal Chemistry A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design The Rhesus Macaque Pediatric SIV Infection Model - A Valuable Tool in Understanding Infant HIV-1 Pathogenesis and for Designing Pediatric HIV-1 Prevention Strategies
Current HIV Research